Rosen Law Firm Seeks Immutep Investors to Lead Securities Lawsuit

Overview

• A securities class action has been filed accusing Immutep Ltd. of making false or misleading public statements about the TACTI-004 cancer trial, including claims in a January SEC filing that the study showed “strong operational progress.”
• Plaintiffs contend Immutep had internal clinical data and analyses that increased the risk the trial would miss its primary efficacy or safety endpoints, a fact they say was not disclosed to investors.
• The Rosen Law Firm is soliciting U.S. purchasers of Immutep American Depositary Receipts from the alleged class period to join the suit and to seek appointment as lead plaintiff under a court deadline.
• No class has been certified and the lawsuit’s allegations remain unproven; the firm notes potential recoveries would proceed on a contingency-fee basis so investors would not pay out-of-pocket to join now.
• The complaint centers on disclosure practices by a clinical-stage drug developer, a process that can affect investor confidence and may prompt closer scrutiny of future SEC filings and trial-update communications.